Molecular Dynamics News
-
CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development
Prominent within the field of computational biology, CD ComputaBio, unveils its cutting-edge Antibody Drug Design Services and Antibody Development solutions. Driven by an unwavering commitment to advancing precision medicine, the company stands at the forefront of redefining therapeutic strategies and expediting drug discovery processes, fostering innovation within the healthcare industry. In ...
-
CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI
CD ComputaBio, a reputable computational service provider in the field of biology, has proudly announced the launch of its Antibody De Novo Design technology, marking a pivotal moment in the field of drug discovery and development. This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge ...
-
CD Computabio Unleashes the Power of Computational Biology with Innovative Virtual Screening Service
CD Computabio, a prominent provider of computational biology solutions, is excited to introduce its virtual screening service based on pharmacophore fragments. This approach is poised to revolutionize the field of drug discovery by offering researchers an efficient and cost-effective solution for identifying promising drug candidates. In the early stages of drug development, virtual screening ...
-
Accelerating Drug Development with CD ComputaBio's Advanced Drug Design and CADD Solutions
CD ComputaBio, a reputable computational service provider in the field of biology, is dedicated to supporting research and trials by offering access to the latest software, technologies, and expertise at competitive prices and with fast turnaround times for researchers. Recently, the company introduced a series of state-of-the-art services in Drug Design and Computer-Aided Drug Design (CADD) with ...
-
CD ComputaBio Boosts Small Molecule Drug Development with Protein-Small Molecule Docking Service
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. The company is pleased to announce the launch of the Protein-Small Molecule Docking service, designed to help customers quickly ...
-
CD ComputaBio Introduces AutoDock, a Powerful Molecular Docking Software
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise at competitive prices and with fast turnarounds for researchers. The company is ready to support your molecular docking projects with its innovative AutoDock software. Autodock is an ...
-
Pronalyse Announces the Launch of Epitope Mapping Service Utilizing HDX-MS Technology
Pronalyse is a subdivision of Creative Proteomics, an integrated CRO company with rich experience in providing drug development services. Based on years of experience supporting protein characterization research, Creative Proteomics Pronalyse has launched the epitope mapping service utilizing HDX-MS, allowing linear and conformational epitope characterization with high resolution and the highest ...
-
Alfa Chemistry Combines the Power of Computational Chemistry for Multiple Medical Applications
Computational chemistry, a branch of chemistry that applies computer simulation to assist in solving chemical problems, is a heated topic in the modern scientific community. Possessing a powerful team of experts in chemistry, biology, mathematics, crystallography, and pharmacology, Alfa Chemistry focuses on combining the power of computational chemistry with a variety of research focuses on ...
-
Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
Cellworks Group Inc., a leader in Personalized Therapy Biosimulation, today announced the launch of its Precision Drug Development business units aimed at accelerating time-to-market for drug development and reviving previously studied but unapproved pharmaceutical assets through predictive biosimulation. The two new business units will use Cellworks’ biosimulation platform and ...
-
CD ComputaBio Releases AutoDock Vina Software to Accelerate Molecular Docking Projects
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise with competitive prices and fast turnarounds for researchers. The company has recently announced the introduction of its Autodock Vina software, designed to predict the mechanism of small ...
-
EPSRC-funded software for research communities project to position OpenMM community at forefront of latest CADD developments
Atomistic simulations constitute one of the primary uses of high-performance computing in research, as they establish the foundation of Research and Development procedures in the chemical and biological sectors. Among the plethora of open-source academic software, OpenMM has the quickest rate of growth due to its excellent tradeoff between extensibility via a robust user interface, and ...
-
ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a study that examined how Differentiation Scoring (DS) derived from key myeloid biomarkers in individual Myelodysplastic Syndrome (MDS) patients using the Cellworks Platform and Computational Biology Model (CBM) can predict response to Hypomethylating Agents (HMA). In ...
-
CD ComputaBio Introduces PyMOL Software for Bioinformatics Analysis
CD ComputaBio, a reliable computational biology service provider in New York, is committed to assisting research and trials, as well as providing access to the latest software, technologies, and expertise with competitive prices and fast turnarounds for researchers. The company has announced the introduction of the PyMOL software, a powerful utility for studying proteins, DNA, and other ...
-
Cellworks Therapy Biosimulation Study Reveals Promising New Biomarkers for TMZ Resistance in Glioblastoma Patients
Cellworks Group Inc. a leader in Precision Drug Development and Personalized Therapy Biosimulation, today announced results from a Cellworks biosimulation pilot study, which examined the impact of mismatch repair deficiency (MRD) on survival of temozolomide (TMZ)-treated patients with MGMT methylated (m-MGMT) glioblastoma (GBM). The biosimulation study validated that TMZ does not trigger ...
-
Structure-based Drug Design is an Essential Tool for Quicker and More Cost-Efficient Lead Discovery
As an active player in the chemical industry, Alfa Chemistry decided to combine the power of computational chemistry with drug design and synthesis. This move aims to largely enhance the overall drug discovery efficiency and open up new possibilities for the pharmaceutical industry. Fairly recently, the company launched a series of structure-based drug design (SBDD) services, showing capabilities ...
-
CD ComputaBio Introduces Four Docking Software for Drug Development
CD ComputaBio, a reliable computational service provider in the field of biology, is committed to assisting research and trials, as well as accessing the latest software, technologies, and expertise at a competitive price and fast turnaround for researchers. Molecular docking is a popular technique in drug design for predicting both binding patterns and binding affinity. CD ComputaBio has ...
-
Leveraging protein DNA/RNA interactions in drug discovery
The field of protein DNA/RNA interactions is an expanding area of research. These interactions affect fundamental processes and as a result, relevant protein DNA/RNA processing complexes and their associated mechanisms provide interesting therapeutic targets to researchers. However, due to the complex and often delicate nature of these systems, traditionally researchers haven’t had ...
-
AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX2-73) in restoring key neurodegenerative pathways
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference (AAIC 2022) in San Diego, in ...
-
Foundation Models for Proteins: Cyrus, OpenFold and the future of biologics
Recent advances in the architecture and scale of AI are leading us from the era of narrowly focused AI (e.g. text auto-complete, immune epitope prediction in a protein sequence, antibody domain detection) to broader models with applications across domains from sales and marketing to medical diagnostics. In protein biochemistry these are the “AIFold” models such as AlphaFold2, ...
-
Job Opening: Scientist – Medicinal Chemistry and Computational Design
What we do: Early Charm creates, owns, and operates businesses that convert science into revenue. We are the management team, the operators, and the entrepreneurs. We do not write checks and just pop in for board meetings. We show up to our labs, our production facilities, and our offices every day to do all the heavy lifting in our portfolio companies. Our scientists and engineers work across ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you